Table 1.
A list of investigational agents in clinical trials that target cancer stem cell specific signaling pathways.
| Drug name | Cancer type | Signaling pathways | Phase | NCT identification numbers in www.clinicaltrials.gov |
|---|---|---|---|---|
| MK0752 | Advanced Breast Cancer Other Solid Tumors |
Notch (γ-secretase inhibitor) | I | NCT00106145 |
| PF-03084014 | Leukemia, Lymphoid Leukemia, T-Cell Solid Tumors |
Notch (γ-secretase inhibitor) | I | NCT00878189 |
| LBH589 | Thyroid Carcinoma | Histone deacetylase inhibitor | II | NCT01013597 |
| Resveratrol | Colon Cancer | Wnt | I/II | NCT00256334 |
| GDC-0449 | Metastatic Colorectal Cancer | Hedgehog (Inhibits SMO) | II | NCT00636610 |
| Solid Cancers | Hedgehog (Inhibits SMO) | I | NCT00968981 | |
| Basal Cell Carcinoma | Hedgehog (Inhibits SMO) | II | NCT00833417 | |
| BMS-833923 (XL139) | Basal Cell Carcinoma | Hedgehog (small molecule SMO inhibitor) | I | NCT00670189 |
| PF-04449913 | Hematologic Malignancies | Hedgehog (small molecule inhibitor of SMO) | I | NCT00953758 |
| IPI-926 | Advanced and/or Metastatic Solid Tumor Malignancies |
Hedgehog (Cyclopamine-derived SMO inhibitor) | I | NCT00761696 |
| Rapamycin | HER-2 Receptor Positive Breast Cancer | IL2 receptor (inhibits mTOR) | II | NCT00411788 |
A list of current investigational agents at various phases of clinical trials that target specific stem cell signaling pathways such as Notch, histone deacetylase, Wnt, Hedgehog, and mTOR.